J. Gilbert

Application of new therapies in Graves' disease and thyroid-associated ophthalmopathy: animal models and translation to human clinical trials.

J. Banga, L. Hegedűs, C. Nielsen, 2008, Thyroid : official journal of the American Thyroid Association.

Clonal relationships between thyroid‐stimulating hormone receptor‐stimulating antibodies illustrate the effect of hypermutation on antibody function

C. Hampe, J. Banga, L. Hegedűs, 2010, Immunology.

Monoclonal Pathogenic Antibodies to the Thyroid-Stimulating Hormone Receptor in Graves’ Disease with Potent Thyroid-Stimulating Activity but Differential Blocking Activity Activate Multiple Signaling Pathways1

Terry J. Smith, J. Banga, A. McGregor, 2006, The Journal of Immunology.

PathwaysBlocking Activity Activate Multiple Signaling Thyroid-Stimulating Activity but Differential Graves' Disease with Potent Thyroid-Stimulating Hormone Receptor in Monoclonal Pathogenic Antibodies to the

Terry J. Smith, A. McGregor, A. Gianoukakis, 2006 .

Evidence for two classes of chromatin-associated Epstein-Barr virus-determined nuclear antigen

T. Spelsberg, T. Sculley, J. Gilbert, 1982, Journal of virology.

Treatment of Graves' disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies.

L. Hegedüs, J. Banga, C. Nielsen, 2009, Clinical immunology.

Chronic exposure in vivo to thyrotropin receptor stimulating monoclonal antibodies sustains high thyroxine levels and thyroid hyperplasia in thyroid autoimmunity‐prone HLA‐DRB1*0301 transgenic mice

C. David, Y. Kong, J. Gilbert, 2007, Immunology.

Treatment of autoimmune hyperthyroidism in a murine model of Graves' disease with tumor necrosis factor-family ligand inhibitors suggests a key role for B cell activating factor in disease pathology.

S. Kalled, J. Banga, P. Rennert, 2006, Endocrinology.

Dynamics of thyroid-stimulating and -blocking antibodies to the thyrotropin receptor in a murine model of Graves' disease.

J. Banga, A. McGregor, J. Gilbert, 2004, Endocrinology.